Renvela, generically known as sevelamer carbonate, is a phosphate binder medication primarily used to treat hyperphosphatemia (high blood phosphate levels) in patients with chronic kidney disease (CKD), especially those on dialysis. It works by binding to dietary phosphate in the gastrointestinal tract, thereby preventing its absorption into the bloodstream. This action helps manage and maintain healthy phosphate levels in the body, which is crucial for patients with impaired kidney function, as excessive phosphate can lead to serious health issues, including bone and cardiovascular diseases. Renvela is available in both tablet and powder form, offering flexibility in administration according to patient preference and needs.